✦ LIBER ✦

Long-term response with everolimus for metastatic renal cell carcinoma refractory to sunitinib

✍ Scribed by Ana M. Molina; Michelle S. Ginsberg; Robert J. Motzer

Book ID: 107577255
Publisher: Springer US
Year: 2010
Tongue: English
Weight: 214 KB
Volume: 28
Category: Article
ISSN: 1357-0560
DOI: 10.1007/s12032-010-9640-y

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Long-term response with sunitinib for me

Long-term response with sunitinib for metastatic renal cell carcinoma

✍ Ellen A. Ronnen; G. Varuni Kondagunta; Michelle S. Ginsberg; Paul Russo; Robert 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 154 KB

Long-term stable disease in metastatic r

Long-term stable disease in metastatic renal cell carcinoma: sorafenib sequenced to sunitinib and everolimus: a case study

✍ Joachim Beck; Joaquim Bellmunt; Bernard Escudier 📂 Article 📅 2010 🏛 Springer US 🌐 English ⚖ 534 KB

Case of complete response to everolimus

Case of complete response to everolimus for metastatic renal cell carcinoma

✍ Kazuhiro Iwasaki; Wataru Obara; Tomoaki Fujioka 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 398 KB

Sorafenib in patients with metastatic re

Sorafenib in patients with metastatic renal cell carcinoma refractory to either sunitinib or bevacizumab

✍ Jorge A. Garcia; Thomas E. Hutson; Paul Elson; C. Lance Cowey; Timothy Gilligan; 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 249 KB 👁 2 views

Phase 1 trial of everolimus plus sunitin

Phase 1 trial of everolimus plus sunitinib in patients with metastatic renal cell carcinoma

✍ Ana M. Molina; Darren R. Feldman; Martin H. Voss; Michelle S. Ginsberg; Michael 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 817 KB

Prognostic nomogram for sunitinib in pat

Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma

✍ Robert J. Motzer; Ronald M. Bukowski; Robert A. Figlin; Thomas E. Hutson; M. Dro 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 115 KB 👁 3 views

## Abstract ## BACKGROUND. In a randomized, phase 3 trial, sunitinib demonstrated superior efficacy over interferon‐alfa as first‐line therapy in patients with metastatic clear‐cell renal cell carcinoma (RCC). On the basis of outcome data from that trial, the authors developed a nomogram for predi